The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

The management of Leishmania donova ni (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug-unresponsiveness, leading to increasing treatment ...

Homozygous familial hypercholesterolaemia affects approximately 30 000 individuals worldwide.1,2 Patients have untreated high plasma LDL cholesterol over 10 mmol/L; physical signs include arcus ...

As a consequence, they lower the hepatic cholesterol pool and promote the expression of LDL receptors in the liver. Bile acid sequestrants are the safest lipid-lowering drugs but have frequent ...

1 Department of Neurology, Wuhan No. 1 Hospital, Wuhan, China 2 The First Clinical Medical Institute, Hubei University of Chinese Medicine, Wuhan, China Introduction/Aims: Myasthenia Gravis (MG) is a ...

PCSK9 reduces the number of low-density lipoprotein (LDL) receptors, increasing circulating ... Treatment with the PCSK9-blocking antibody, evolocumab — which is approved to treat ...

Also, we decipher the role of antibodies in the attachment of the virus to receptors, internalization, and uncoating process, providing insight into virus neutralization mechanisms. Moreover, ...